Utilisation des anticoagulants directs chez le sujet âgé : le point de vue du cardiologue

Anderson FA Jr, Wheeler HB, Goldberg RJ, et al (1991) A population-based perspective of the hospital incidence and casefatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med151:933–8 Stein PD, Hull RD, Kayali F, et al (2004) Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 164:2260–5 Heit JA, Mohr DN, Silverstein MD, et al (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160:761–8 Kyrle PA, Eichinger S (2012) Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemostas 108:1061–4 Anderson FA Jr, Spencer FA (2003) Risk factors for venous hromboembolism. Circulation 107:I9–I16 Goldhaber SZ (2010) Risk factors for venous thromboembolism. J Am Coll Cardiol 56:1–7 Lloyd-Jones DM, Wang TJ, Leip EP, et al (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:1042–6 Go AS, Hylek EM, Phillips KA, et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–5 Vidaillet H, Granada JF, Chyou Po-H, et al (2002) A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365–70 Bauersachs RM (2012) Use of anticoagulants in elderly patients. Thromb Res 129:107–15 Van Walraven C, Hart RG, Singer DE, et al (2002) Oral anticoagulants vs aspirin in nonvalvular AF: an individual patient meta-analysis. JAMA 288:2441–8 Mant J, Hobbs FDR, Fletcher K, et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with AF (the Birmingham AF Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370:493–503 Connolly SJ, Pogue J, Hart RG, et al (2009) Effect of clopidogrel added to aspirin in patients with AF. N Engl J Med 360:2066–78 Ng KH, Hart RG, Eikelboom JW (2013) Anticoagulation in patients aged = 75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther 2:135–49 Cairns JA (2013) Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices. Can J Cardiol 29:1165–72 Limdi NA, Beasley TM, Baird MF, et al (2009) Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20:912–21 Denny SD, Kuchibhatla MN, Cohen HJ (2006) Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 119:327–34 Adverse drug reaction–related hospitalizations among seniors, 2006 to 2011. Ottawa (ON): Canadian Institute for Health Information; 2013. Available: https://secure.cihi.ca/free_products/ Hospitalizations%20for%20ADR-ENweb.pdf Hanon O, Assayag P, Belmin J, et al (2013) Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 106:303–23 Eikelboom JW, Wallentin L, Connolly SJ, et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–72 Geldhof V, Vandenbriele C, Verhamme P, Vanassche T (2014) Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 12:21–30